(Q34047983)

30 July 2017

0 references

The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis (English)

1 reference

30 July 2017

1 reference

1 reference

1 reference

S Teasdale

5

0 references

Joseph Firth

J Firth

1

0 references

Brendon Stubbs

B Stubbs

2

0 references

Michael Berk

M Berk

6

0 references

Simon Rosenbaum

4

S Rosenbaum

1 reference

ORCID Public Data File 2021

30 July 2017

1 reference

author name string

J Sarris

3

1 reference

PubMed ID

28202095

30 July 2017

A R Yung

7

1 reference

PubMed ID

28202095

30 July 2017

language of work or name

English

0 references

publication date

16 February 2017

1 reference

30 July 2017

Psychological Medicine

1 reference

30 July 2017

47

1 reference

30 July 2017

9

1 reference

30 July 2017

1515-1527

1 reference

Is it time to trial vitamin D supplements for the prevention of schizophrenia?

30 July 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Lack of effect of inositol treatment in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Vitamin B6 Treatment in Acute Neuroleptic-Induced Akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

The NIMH-MATRICS consensus statement on negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

The Emerging Field of Nutritional Mental Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Lack of effect of chromium supplementation on mental state and body weight in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Diet, exercise and the metabolic syndrome in schizophrenia: A cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Enhancement of recovery from psychiatric illness by methylfolate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners. Randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Plasma manganese, selenium, zinc, copper, and iron concentrations in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

The dietary pattern of patients with schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Emerging Treatments in Schizophrenia: Highlights from Recent Supplementation and Prevention Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Elevated homocysteine level in first-episode schizophrenia patients--the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

The treatment of tardive dyskinesia--a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Serum vitamin D and hippocampal gray matter volume in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Relemed: sentence-level search engine with relevance score for the MEDLINE database of biomedical articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Nutritional medicine as mainstream in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Vitamin-mineral treatment of attention-deficit hyperactivity disorder in adults: double-blind randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Shaken but unstirred? Effects of micronutrients on stress and trauma after an earthquake: RCT evidence comparing formulas and doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Folate supplementation in schizophrenia: A possible role for MTHFR genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

Enough is enough: Stop wasting money on vitamin and mineral supplements

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Broad-spectrum micronutrient formulas for the treatment of psychiatric symptoms: a systematic review

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Vitamin E in the treatment of tardive dyskinesia: a replication study

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Inositol 6 g daily may be effective in depression but not in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

The pro-oxidant chemistry of the natural antioxidants vitamin C, vitamin E, carotenoids and flavonoids

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Homocysteine levels in schizophrenia and affective disorders-focus on cognition

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

The effect of vitamin E addition to acute neuroleptic treatment on the emergence of extrapyramidal side effects in schizophrenic patients: an open label study

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Clinical correlates of vitamin D deficiency in established psychosis.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Magic bullet thinking--why do we continue to perpetuate this fallacy?

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Efficacy of Zinc Sulfate as an Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia: A Double-Blind Randomized Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Utilization of the PICO framework to improve searching PubMed for clinical questions

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Adjunctive Taurine in First-Episode Psychosis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study.

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS0033291717000022

7 January 2021

10.1017/S0033291717000022

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

28202095